Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H9ClF3NO2 |
| Molecular Weight | 315.675 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC3CC3
InChI
InChIKey=XPOQHMRABVBWPR-ZDUSSCGKSA-N
InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. | 2001 Aug |
|
| Antiviral drugs: current state of the art. | 2001 Aug |
|
| Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach? | 2001 Jan-Feb |
|
| [Drug interactions with antiretroviral agents]. | 2001 May-Jun |
|
| Other issues: penetration into sanctuary sites, immune reconstitution and NNRTI sequencing. | 2001 Nov |
|
| Factors affecting adherence and convenience in antiretroviral therapy. | 2001 Nov |
|
| Comparison of NNRTIs in antiretroviral-experienced patients. | 2001 Nov |
|
| Comparison of NNRTIs in antiretroviral-naïve patients. | 2001 Nov |
|
| The role of NNRTIs in antiretroviral combination therapy: an introduction. | 2001 Nov |
|
| Thiosugars. VIII. Preparation of new 4'-thio-L-lyxo pyrimidine nucleoside analogues. | 2001 Sep |
|
| Efavirenz-induced psychosis. | 2001 Sep 28 |
|
| Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. | 2001 Sep 28 |
|
| Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. | 2001 Sep 28 |
Sample Use Guides
SUSTIVA should be taken orally once daily on an empty stomach, preferably at bedtime. • Recommended adult dose: 600 mg. • With voriconazole, increase voriconazole maintenance dose to 400 mg every 12 hours and decrease SUSTIVA dose to 300 mg once daily using the capsule formulation.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000009948
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
LIVERTOX |
341
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
WHO-ATC |
J05AR11
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
NDF-RT |
N0000175460
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
EMA ASSESSMENT REPORTS |
SUSTIVA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
EMA ASSESSMENT REPORTS |
ATRIPLA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
NDF-RT |
N0000175463
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (EFV/FTC/TEN)
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
WHO-VATC |
QJ05AR11
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
WHO-ATC |
J05AR06
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
WHO-VATC |
QJ05AR06
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.2
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
NCI_THESAURUS |
C97453
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
WHO-VATC |
QJ05AG03
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
WHO-ATC |
J05AG03
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
EMA ASSESSMENT REPORTS |
STOCRIN (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
||
|
EMA ASSESSMENT REPORTS |
EFAVIRENZ TEVA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
N0000182140
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | Cytochrome P450 2C19 Inhibitors [MoA] | ||
|
CHEMBL223228
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
154598-52-4
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
EFAVIRENZ
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | Description: White to slightly pink powder.Solubility: Practically insoluble in water, freely soluble in methanol.Category. Antiretroviral (Non-nucleoside Reverse Transcriptase Inhibitor).Storage. Efavirenz should be kept in a well-closed container, protected from light.Additional information: Efavirenz may exhibit polymorphism.Requirements: Definition: Efavirenz contains not less than 97.0% and not more than 103.0% of C14H9ClF3NO2, calculated with reference to thedried substance.Manufacture: The production method is validated to ensure that the substance is the (4S)-enantiomer. | ||
|
SUB06463MIG
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
64139
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
C098320
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
195085
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | RxNorm | ||
|
N0000182141
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | Cytochrome P450 3A4 Inhibitors [MoA] | ||
|
M4839
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | Merck Index | ||
|
154598-52-4
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
7718
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
C29027
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
EFAVIRENZ
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
N0000185504
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | Cytochrome P450 2C9 Inhibitors [MoA] | ||
|
N0000187064
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | Cytochrome P450 2B6 Inducers [MoA] | ||
|
154598-52-4
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
DB00625
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | |||
|
N0000190118
Created by
admin on Mon Oct 21 19:49:24 UTC 2019 , Edited by admin on Mon Oct 21 19:49:24 UTC 2019
|
PRIMARY | Cytochrome P450 3A Inducers [MoA] |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
